Advertisement


Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma

2014 ASH Annual Meeting

Advertisement

Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Results for the 1703 Phase Ib/II Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma,” presented by Paul G. Richardson, MD; abstract 84, “Safety and Efficacy of Daratumumab With Lenalidomide and Dexamethasone in Relapsed or Relapsed/ Refractory Multiple Myeloma,” presented by Torben Plesner, MD; and “A Phase Ib Dose Escalation Trial of SAR650984 (Anti–CD-38 mAb) in Combination With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma,” presented by Thomas G. Martin III, MD.



Related Videos

Lymphoma
Myelodysplastic Syndromes

Richard M. Stone, MD, on the SWOG S1117 Study

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “...

Lymphoma

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in ...

Lymphoma

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “

Leukemia
Lymphoma

Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma

Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituxima...

Lymphoma

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504,


Advertisement



Advertisement